Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy.
Cancer cells mainly rely on glycolysis for energetic needs, and mitochondrial ATP production is almost inactive. However, cancer cells require the integrity of mitochondrial functions for their survival, such as the maintenance of the internal membrane potential gradient (DeltaPsim). It thus may be predicted that DeltaPsim regeneration should depend on cellular capability to produce sufficient ATP by upregulating glycolysis or recruiting oxidative phosphorylation (OXPHOS). To investigate this hypothesis, we compared the response to an anticancer agent chloroethylnitrosourea (CENU) of two transformed cell lines: HepG2 (hepatocarcinoma) with a partially differentiated phenotype and 143B (osteosarcoma) with an undifferentiated one. These cells types differ by their mitochondrial OXPHOS background; the most severely impaired being that of 143B cells. Treatment effects were tested on cell proliferation, O(2) consumption/ATP production coupling, DeltaPsim maintenance, and global metabolite profiling by NMR spectroscopy. Our results showed an OXPHOS uncoupling and a lowered DeltaPsim, leading to an increased energy request to regenerate DeltaPsim in both models. However, energy request could not be met by undifferentiated cells 143B, which ATP content decreased after 48 h leading to cell death, while partially differentiated cells (HepG2) could activate their oxidative metabolism and escape chemotherapy. We propose that mitochondrial OXPHOS background confers a survival advantage to more differentiated cells in response to chemotherapy. This suggests that the mitochondrial bioenergetic background of tumors should be considered for anticancer treatment personalization.
Inserm U694, University Hospital Center, Angers, France.
Dominique
D
Loiseau
Daniel
D
Morvan
Arnaud
A
Chevrollier
Aicha
A
Demidem
Olivier
O
Douay
Pascal
P
Reynier
Georges
G
Stepien
D000255:Adenosine Triphosphate / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism*; D002454:Cell Differentiation; D049109:Cell Proliferation; D019069:Cell Respiration; D002470:Cell Survival / Q000187:drug effects; D004734:Energy Metabolism; D005038:Ethylnitrosourea / Q000031:analogs & derivatives / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D019344:Lactic Acid / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D053078:Membrane Potential, Mitochondrial; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism*; D010085:Oxidative Phosphorylation; D019289:Pyruvic Acid / Q000378:metabolism; D014407:Tumor Cells, Cultured
C017139:1-(2-chloroethyl)-1-nitrosourea; D019344:Lactic Acid; D019289:Pyruvic Acid; D000255:Adenosine Triphosphate; D005947:Glucose; D005038:Ethylnitrosourea